• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Part-Timers Stay Away From D. Sloan

Anonymous

Guest
Now why would anyone want to work part-time for D. Sloan? Full-timers had many issues with her and have left or waited for severance. If you are interested in a Part-time with Eisai, I would think about why you would put yourself at risk to work at a miserable environment with such a person who pretends to be a District Manager. You will not learn to be an excellent pharmaceutical representative within the industry. Plus with such a track record you will have a hard time locating another job. Please check more references. Good luck!
 

<



Now why would anyone want to work part-time for D. Sloan? Full-timers had many issues with her and have left or waited for severance. If you are interested in a Part-time with Eisai, I would think about why you would put yourself at risk to work at a miserable environment with such a person who pretends to be a District Manager. You will not learn to be an excellent pharmaceutical representative within the industry. Plus with such a track record you will have a hard time locating another job. Please check more references. Good luck!

What p/t positions? Eisai is really cutting back!